메뉴 건너뛰기




Volumn 14, Issue 1, 2016, Pages

Advances in immunotherapy for melanoma

Author keywords

Anti PD 1; Immunotherapy; Ipilimumab; Melanoma; Nivolumab; Pembrolizumab

Indexed keywords

ANTINEOPLASTIC AGENT; ATEZOLIZUMAB; BIOLOGICAL MARKER; CD27 ANTIGEN; DACARBAZINE; DURVALUMAB; EPACADOSTAT; INTERFERON; IPILIMUMAB; MEDI 6883; NIVOLUMAB; PEGINTERFERON; PEMBROLIZUMAB; PF 05082566; PLACEBO; PROGRAMMED DEATH 1 RECEPTOR; SARGRAMOSTIM; TALIMOGENE LAHERPAREPVEC; TICILIMUMAB; UNCLASSIFIED DRUG; VARILILUMAB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY;

EID: 84957097035     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/s12916-016-0571-0     Document Type: Short Survey
Times cited : (116)

References (85)
  • 1
    • 79952613370 scopus 로고    scopus 로고
    • Systematic review of medical treatment in melanoma: current status and future prospects
    • Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist. 2011;16:5-24.
    • (2011) Oncologist , vol.16 , pp. 5-24
    • Garbe, C.1    Eigentler, T.K.2    Keilholz, U.3    Hauschild, A.4    Kirkwood, J.M.5
  • 2
    • 0033989205 scopus 로고    scopus 로고
    • Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma
    • Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18:158-66.
    • (2000) J Clin Oncol , vol.18 , pp. 158-166
    • Middleton, M.R.1    Grob, J.J.2    Aaronson, N.3    Fierlbeck, G.4    Tilgen, W.5    Seiter, S.6
  • 3
    • 0022349817 scopus 로고
    • Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer
    • Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985;313:1485-92.
    • (1985) N Engl J Med , vol.313 , pp. 1485-1492
    • Rosenberg, S.A.1    Lotze, M.T.2    Muul, L.M.3    Leitman, S.4    Chang, A.E.5    Ettinghausen, S.E.6
  • 4
    • 0026660727 scopus 로고
    • Image analysis of stage 1 melanoma (1.00-2.50 mm): lymphocytic infiltrates related to metastasis and survival
    • Pastorfide GC, Kibbi AG, de Roa AL, Barnhill RL, Sober AJ, Mihm Jr MC, et al. Image analysis of stage 1 melanoma (1.00-2.50 mm): lymphocytic infiltrates related to metastasis and survival. J Cutan Pathol. 1992;19:390-7.
    • (1992) J Cutan Pathol , vol.19 , pp. 390-397
    • Pastorfide, G.C.1    Kibbi, A.G.2    Roa, A.L.3    Barnhill, R.L.4    Sober, A.J.5    Mihm, M.C.6
  • 5
    • 0020583054 scopus 로고
    • Factors associated with death from melanoma from 2 to 5 years following diagnosis in clinical stage I patients
    • Sober AJ, Day Jr CL, Fitzpatrick TB, Lew RA, Kopf AW, Mihm Jr MC. Factors associated with death from melanoma from 2 to 5 years following diagnosis in clinical stage I patients. J Invest Dermatol. 1983;80 Suppl:53s-5s.
    • (1983) J Invest Dermatol , vol.80 , pp. 53s-55s
    • Sober, A.J.1    Day, C.L.2    Fitzpatrick, T.B.3    Lew, R.A.4    Kopf, A.W.5    Mihm, M.C.6
  • 6
    • 0033024863 scopus 로고    scopus 로고
    • High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993
    • Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17:2105-16.
    • (1999) J Clin Oncol , vol.17 , pp. 2105-2116
    • Atkins, M.B.1    Lotze, M.T.2    Dutcher, J.P.3    Fisher, R.I.4    Weiss, G.5    Margolin, K.6
  • 7
    • 33745632047 scopus 로고    scopus 로고
    • Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites
    • Harlin H, Kuna TV, Peterson AC, Meng Y, Gajewski TF. Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites. Cancer Immunol Immunother. 2006;55:1185-97.
    • (2006) Cancer Immunol Immunother , vol.55 , pp. 1185-1197
    • Harlin, H.1    Kuna, T.V.2    Peterson, A.C.3    Meng, Y.4    Gajewski, T.F.5
  • 8
    • 84883863501 scopus 로고    scopus 로고
    • Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells
    • 200ra116
    • Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med. 2013;5:200ra116.
    • (2013) Sci Transl Med , vol.5
    • Spranger, S.1    Spaapen, R.M.2    Zha, Y.3    Williams, J.4    Meng, Y.5    Ha, T.T.6
  • 9
    • 0141953992 scopus 로고    scopus 로고
    • B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma
    • Strome SE, Dong H, Tamura H, Voss SG, Flies DB, Tamada K, et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res. 2003;63:6501-5.
    • (2003) Cancer Res , vol.63 , pp. 6501-6505
    • Strome, S.E.1    Dong, H.2    Tamura, H.3    Voss, S.G.4    Flies, D.B.5    Tamada, K.6
  • 10
    • 34848900497 scopus 로고    scopus 로고
    • Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs
    • Wong RM, Scotland RR, Lau RL, Wang C, Korman AJ, Kast WM, et al. Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. Int Immunol. 2007;19:1223-34.
    • (2007) Int Immunol , vol.19 , pp. 1223-1234
    • Wong, R.M.1    Scotland, R.R.2    Lau, R.L.3    Wang, C.4    Korman, A.J.5    Kast, W.M.6
  • 11
    • 84873372202 scopus 로고    scopus 로고
    • Advances in targeting cell surface signalling molecules for immune modulation
    • Yao S, Zhu Y, Chen L. Advances in targeting cell surface signalling molecules for immune modulation. Nat Rev Drug Discov. 2013;12:130-46.
    • (2013) Nat Rev Drug Discov , vol.12 , pp. 130-146
    • Yao, S.1    Zhu, Y.2    Chen, L.3
  • 13
    • 68149155982 scopus 로고    scopus 로고
    • Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies
    • Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med. 2009;206:1717-25.
    • (2009) J Exp Med , vol.206 , pp. 1717-1725
    • Peggs, K.S.1    Quezada, S.A.2    Chambers, C.A.3    Korman, A.J.4    Allison, J.P.5
  • 14
    • 0038153907 scopus 로고    scopus 로고
    • Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
    • Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 2003;100:8372-7.
    • (2003) Proc Natl Acad Sci U S A , vol.100 , pp. 8372-8377
    • Phan, G.Q.1    Yang, J.C.2    Sherry, R.M.3    Hwu, P.4    Topalian, S.L.5    Schwartzentruber, D.J.6
  • 15
    • 24944459890 scopus 로고    scopus 로고
    • Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4
    • Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol. 2005;23:6043-53.
    • (2005) J Clin Oncol , vol.23 , pp. 6043-6053
    • Attia, P.1    Phan, G.Q.2    Maker, A.V.3    Robinson, M.R.4    Quezado, M.M.5    Yang, J.C.6
  • 16
  • 18
    • 79959772576 scopus 로고    scopus 로고
    • Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
    • Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517-26.
    • (2011) N Engl J Med , vol.364 , pp. 2517-2526
    • Robert, C.1    Thomas, L.2    Bondarenko, I.3    O'Day, S.4    Weber, J.5    Garbe, C.6
  • 19
    • 84928917822 scopus 로고    scopus 로고
    • Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma
    • Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33:1889-4.
    • (2015) J Clin Oncol , vol.33 , pp. 1884-1889
    • Schadendorf, D.1    Hodi, F.S.2    Robert, C.3    Weber, J.S.4    Margolin, K.5    Hamid, O.6
  • 21
    • 84874605864 scopus 로고    scopus 로고
    • Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma
    • Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013;31:616-22.
    • (2013) J Clin Oncol , vol.31 , pp. 616-622
    • Ribas, A.1    Kefford, R.2    Marshall, M.A.3    Punt, C.J.4    Haanen, J.B.5    Marmol, M.6
  • 22
    • 84940746759 scopus 로고    scopus 로고
    • Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
    • Bertrand A, Kostine M, Barnetche T, Truchetet ME, Schaeverbeke T. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13:211.
    • (2015) BMC Med , vol.13 , pp. 211
    • Bertrand, A.1    Kostine, M.2    Barnetche, T.3    Truchetet, M.E.4    Schaeverbeke, T.5
  • 23
    • 84864052441 scopus 로고    scopus 로고
    • Management of immune-related adverse events and kinetics of response with ipilimumab
    • Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30:2691-7.
    • (2012) J Clin Oncol , vol.30 , pp. 2691-2697
    • Weber, J.S.1    Kahler, K.C.2    Hauschild, A.3
  • 24
    • 73149092567 scopus 로고    scopus 로고
    • Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria
    • Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412-20.
    • (2009) Clin Cancer Res , vol.15 , pp. 7412-7420
    • Wolchok, J.D.1    Hoos, A.2    O'Day, S.3    Weber, J.S.4    Hamid, O.5    Lebbe, C.6
  • 25
    • 77954899030 scopus 로고    scopus 로고
    • Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates
    • Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28:3167-75.
    • (2010) J Clin Oncol , vol.28 , pp. 3167-3175
    • Brahmer, J.R.1    Drake, C.G.2    Wollner, I.3    Powderly, J.D.4    Picus, J.5    Sharfman, W.H.6
  • 27
    • 84898973055 scopus 로고    scopus 로고
    • Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab
    • Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32:1020-30.
    • (2014) J Clin Oncol , vol.32 , pp. 1020-1030
    • Topalian, S.L.1    Sznol, M.2    McDermott, D.F.3    Kluger, H.M.4    Carvajal, R.D.5    Sharfman, W.H.6
  • 28
    • 84907558390 scopus 로고    scopus 로고
    • Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial
    • Hodi FS, Sznol M, Kluger HM, McDermott DF, Carvajal RD, Lawrence DP, et al. Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial. J Clin Oncol. 2014;32:5s. suppl; abstr 9002.
    • (2014) J Clin Oncol , vol.32 , pp. 5s
    • Hodi, F.S.1    Sznol, M.2    Kluger, H.M.3    McDermott, D.F.4    Carvajal, R.D.5    Lawrence, D.P.6
  • 29
    • 84879759020 scopus 로고    scopus 로고
    • Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma
    • Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369:134-44.
    • (2013) N Engl J Med , vol.369 , pp. 134-144
    • Hamid, O.1    Robert, C.2    Daud, A.3    Hodi, F.S.4    Hwu, W.J.5    Kefford, R.6
  • 30
    • 84947704341 scopus 로고    scopus 로고
    • Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001.
    • abstr 9005
    • Daud A, Ribas A, Robert C, Hodi FS, Wolchok JD, Joshua AM, et al. Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001. J Clin Oncol. 2015;33:(suppl; abstr 9005).
    • (2015) J Clin Oncol. , vol.33
    • Daud, A.1    Ribas, A.2    Robert, C.3    Hodi, F.S.4    Wolchok, J.D.5    Joshua, A.M.6
  • 31
    • 84931083080 scopus 로고    scopus 로고
    • Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
    • Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16:375-84.
    • (2015) Lancet Oncol , vol.16 , pp. 375-384
    • Weber, J.S.1    D'Angelo, S.P.2    Minor, D.3    Hodi, F.S.4    Gutzmer, R.5    Neyns, B.6
  • 32
    • 84938205998 scopus 로고    scopus 로고
    • Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
    • Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16:908-18.
    • (2015) Lancet Oncol , vol.16 , pp. 908-918
    • Ribas, A.1    Puzanov, I.2    Dummer, R.3    Schadendorf, D.4    Hamid, O.5    Robert, C.6
  • 33
    • 84908354848 scopus 로고    scopus 로고
    • Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
    • Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384:1109-17.
    • (2014) Lancet , vol.384 , pp. 1109-1117
    • Robert, C.1    Ribas, A.2    Wolchok, J.D.3    Hodi, F.S.4    Hamid, O.5    Kefford, R.6
  • 34
    • 84907532904 scopus 로고    scopus 로고
    • A phase 1 study of MEDI4736, an anti-PD-L1 antibody, in patients with advanced solid tumors.
    • abstr 3001^).
    • Lutzky J, Antonia SJ, Blake-Haskins A, Li X, Robbins PB, Shalabi AM, et al. A phase 1 study of MEDI4736, an anti-PD-L1 antibody, in patients with advanced solid tumors. J Clin Oncol. 2014;32(5s):(suppl; abstr 3001^).
    • (2014) J Clin Oncol. , vol.32 , Issue.5
    • Lutzky, J.1    Antonia, S.J.2    Blake-Haskins, A.3    Li, X.4    Robbins, P.B.5    Shalabi, A.M.6
  • 35
    • 84880277245 scopus 로고    scopus 로고
    • Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM).
    • (suppl; abstr 9010).
    • Hamid O, Sosman JA, Lawrence DP, Sullivan RJ, Ibrahim N, Kluger HM, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM). J Clin Oncol. 2013;31:(suppl; abstr 9010).
    • (2013) J Clin Oncol. , vol.31
    • Hamid, O.1    Sosman, J.A.2    Lawrence, D.P.3    Sullivan, R.J.4    Ibrahim, N.5    Kluger, H.M.6
  • 38
    • 84937156354 scopus 로고    scopus 로고
    • Swinging for the fences: long-term survival with ipilimumab in metastatic melanoma
    • Gibney GT, Atkins MB. Swinging for the fences: long-term survival with ipilimumab in metastatic melanoma. J Clin Oncol. 2015;33:1873-7.
    • (2015) J Clin Oncol , vol.33 , pp. 1873-1877
    • Gibney, G.T.1    Atkins, M.B.2
  • 39
  • 40
    • 84941966146 scopus 로고    scopus 로고
    • Characterization of PD-L1 expression and associated T-cell infiltrates in metastatic melanoma samples from variable anatomic sites
    • Kluger HM, Zito CR, Barr ML, Baine MK, Chiang VL, Sznol M, et al. Characterization of PD-L1 expression and associated T-cell infiltrates in metastatic melanoma samples from variable anatomic sites. Clin Cancer Res. 2015;21:3052-60.
    • (2015) Clin Cancer Res , vol.21 , pp. 3052-3060
    • Kluger, H.M.1    Zito, C.R.2    Barr, M.L.3    Baine, M.K.4    Chiang, V.L.5    Sznol, M.6
  • 41
    • 84960396403 scopus 로고    scopus 로고
    • Safety and activity of pembrolizumab in melanoma patients with untreated brain metastases.
    • (suppl; abstr 9009).
    • Kluger HM, Goldberg SB, Sznol M, Tsiouris J, Vortmeyer A, Jilaveanu L, et al. Safety and activity of pembrolizumab in melanoma patients with untreated brain metastases. J Clin Oncol. 2015;33:(suppl; abstr 9009).
    • (2015) J Clin Oncol. , vol.33
    • Kluger, H.M.1    Goldberg, S.B.2    Sznol, M.3    Tsiouris, J.4    Vortmeyer, A.5    Jilaveanu, L.6
  • 43
    • 1842533233 scopus 로고    scopus 로고
    • A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma
    • Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res. 2004;10:1670-7.
    • (2004) Clin Cancer Res , vol.10 , pp. 1670-1677
    • Kirkwood, J.M.1    Manola, J.2    Ibrahim, J.3    Sondak, V.4    Ernstoff, M.S.5    Rao, U.6
  • 44
    • 84869212118 scopus 로고    scopus 로고
    • Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma
    • Eggermont AM, Suciu S, Testori A, Santinami M, Kruit WH, Marsden J, et al. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol. 2012;30:3810-8.
    • (2012) J Clin Oncol , vol.30 , pp. 3810-3818
    • Eggermont, A.M.1    Suciu, S.2    Testori, A.3    Santinami, M.4    Kruit, W.H.5    Marsden, J.6
  • 46
    • 84911411511 scopus 로고    scopus 로고
    • Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group
    • Flaherty LE, Othus M, Atkins MB, Tuthill RJ, Thompson JA, Vetto JT, et al. Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. J Clin Oncol. 2014;32:3771-8.
    • (2014) J Clin Oncol , vol.32 , pp. 3771-3778
    • Flaherty, L.E.1    Othus, M.2    Atkins, M.B.3    Tuthill, R.J.4    Thompson, J.A.5    Vetto, J.T.6
  • 47
    • 84933678156 scopus 로고    scopus 로고
    • Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
    • Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16:522-30.
    • (2015) Lancet Oncol , vol.16 , pp. 522-530
    • Eggermont, A.M.1    Chiarion-Sileni, V.2    Grob, J.J.3    Dummer, R.4    Wolchok, J.D.5    Schmidt, H.6
  • 48
    • 84970925355 scopus 로고    scopus 로고
    • Adjuvant Therapy for High-Risk Melanoma
    • Tarhini AA. Adjuvant Therapy for High-Risk Melanoma. Am J Hematol Oncol. 2014;10:4-13.
    • (2014) Am J Hematol Oncol , vol.10 , pp. 4-13
    • Tarhini, A.A.1
  • 49
    • 84923166043 scopus 로고    scopus 로고
    • Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma
    • Gibney GT, Kudchadkar RR, DeConti RC, Thebeau MS, Czupryn MP, Tetteh L, et al. Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res. 2015;21:712-20.
    • (2015) Clin Cancer Res , vol.21 , pp. 712-720
    • Gibney, G.T.1    Kudchadkar, R.R.2    DeConti, R.C.3    Thebeau, M.S.4    Czupryn, M.P.5    Tetteh, L.6
  • 50
    • 77749279776 scopus 로고    scopus 로고
    • PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
    • Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A. 2010;107:4275-80.
    • (2010) Proc Natl Acad Sci U S A , vol.107 , pp. 4275-4280
    • Curran, M.A.1    Montalvo, W.2    Yagita, H.3    Allison, J.P.4
  • 52
    • 84907498833 scopus 로고    scopus 로고
    • Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL).
    • (suppl; abstr LBA9003^).
    • Sznol M, Kluger HM, Callahan MK, Postow MA, Gordon RA, Segal NH, et al. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). J Clin Oncol. 2014;32(5s):(suppl; abstr LBA9003^).
    • (2014) J Clin Oncol. , vol.32 , Issue.5
    • Sznol, M.1    Kluger, H.M.2    Callahan, M.K.3    Postow, M.A.4    Gordon, R.A.5    Segal, N.H.6
  • 54
    • 84957102501 scopus 로고    scopus 로고
    • An open-label, randomized, phase 2 study of nivolumab given sequentially with ipilimumab in patients with advanced melanoma (Checkmate 064).
    • ECCO-ESMO. 25-29 September 2015. 2015:abstract 23LBA.
    • Hodi FS, Gibney GT, Sullivan R, Sosman JA, Slingluff CL, Lawrence DP, et al. An open-label, randomized, phase 2 study of nivolumab given sequentially with ipilimumab in patients with advanced melanoma (Checkmate 064). ECCO-ESMO. 25-29 September 2015. 2015:abstract 23LBA.
    • Hodi, F.S.1    Gibney, G.T.2    Sullivan, R.3    Sosman, J.A.4    Slingluff, C.L.5    Lawrence, D.P.6
  • 55
    • 84958771685 scopus 로고    scopus 로고
    • Pembrolizumab (MK-3475) plus low-dose ipilimumab (IPI) in patients (pts) with advanced melanoma (MEL) or renal cell carcinoma (RCC): Data from the KEYNOTE-029 phase 1 study.
    • suppl; abstr 3009
    • Atkins MB, Choueiri TK, Hodi FS, Thompson JA, Hwu W, McDermott DF, et al. Pembrolizumab (MK-3475) plus low-dose ipilimumab (IPI) in patients (pts) with advanced melanoma (MEL) or renal cell carcinoma (RCC): Data from the KEYNOTE-029 phase 1 study. J Clin Oncol. 2015;33(5s):(suppl; abstr 3009).
    • (2015) J Clin Oncol. , vol.33 , Issue.5
    • Atkins, M.B.1    Choueiri, T.K.2    Hodi, F.S.3    Thompson, J.A.4    Hwu, W.5    McDermott, D.F.6
  • 56
    • 84922005095 scopus 로고    scopus 로고
    • A phase IB study of ipilimumab with peginterferon alfa-2b for patients with unresectable stages IIIB/C/IV melanoma.
    • (suppl; abstr 9098).
    • Kudchadkar RR, Gibney GT, Dorman D, Merek S, Ramadan H, Chen A, et al. A phase IB study of ipilimumab with peginterferon alfa-2b for patients with unresectable stages IIIB/C/IV melanoma. J Clin Oncol. 2014;32(5s):(suppl; abstr 9098).
    • (2014) J Clin Oncol. , vol.32 , Issue.5
    • Kudchadkar, R.R.1    Gibney, G.T.2    Dorman, D.3    Merek, S.4    Ramadan, H.5    Chen, A.6
  • 57
    • 84908664534 scopus 로고    scopus 로고
    • Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial
    • Hodi FS, Lee S, McDermott DF, Rao UN, Butterfield LH, Tarhini AA, et al. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA. 2014;312:1744-53.
    • (2014) JAMA , vol.312 , pp. 1744-1753
    • Hodi, F.S.1    Lee, S.2    McDermott, D.F.3    Rao, U.N.4    Butterfield, L.H.5    Tarhini, A.A.6
  • 58
    • 84957094227 scopus 로고    scopus 로고
    • Study of anti-PD-1 antibody pembrolizumab and pegylated-interferon alfa-2b (Peg-IFN) for advanced melanoma.
    • (suppl; abstr e20018).
    • Zarour HM, Tawbi H, Tarhini AA, Wang H, Sander C, Rose A, et al. Study of anti-PD-1 antibody pembrolizumab and pegylated-interferon alfa-2b (Peg-IFN) for advanced melanoma. J Clin Oncol. 2015;33:(suppl; abstr e20018).
    • (2015) J Clin Oncol. , vol.33
    • Zarour, H.M.1    Tawbi, H.2    Tarhini, A.A.3    Wang, H.4    Sander, C.5    Rose, A.6
  • 59
  • 60
    • 84936821506 scopus 로고    scopus 로고
    • Survival, safety, and response patterns in a phase 1b multicenter trial of talimogene laherparepvec (T-VEC) and ipilimumab (IPI) in previously untreated, unresected stage IIIB-IV melanoma.
    • (suppl; abstr 9063).
    • Puzanov I, Milhem MM, Andtbacka RHI, Minor DR, Hamid O, Li A, et al. Survival, safety, and response patterns in a phase 1b multicenter trial of talimogene laherparepvec (T-VEC) and ipilimumab (IPI) in previously untreated, unresected stage IIIB-IV melanoma. J Clin Oncol. 2015;33:(suppl; abstr 9063).
    • (2015) J Clin Oncol. , pp. 33
    • Puzanov, I.1    Milhem, M.M.2    Andtbacka, R.H.I.3    Minor, D.R.4    Hamid, O.5    Li, A.6
  • 61
    • 0142137237 scopus 로고    scopus 로고
    • Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
    • Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med. 2003;9:1269-74.
    • (2003) Nat Med , vol.9 , pp. 1269-1274
    • Uyttenhove, C.1    Pilotte, L.2    Theate, I.3    Stroobant, V.4    Colau, D.5    Parmentier, N.6
  • 62
    • 77951718214 scopus 로고    scopus 로고
    • Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity
    • Liu X, Shin N, Koblish HK, Yang G, Wang Q, Wang K, et al. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood. 2010;115:3520-30.
    • (2010) Blood , vol.115 , pp. 3520-3530
    • Liu, X.1    Shin, N.2    Koblish, H.K.3    Yang, G.4    Wang, Q.5    Wang, K.6
  • 63
    • 84895900553 scopus 로고    scopus 로고
    • Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2,3-dioxygenase (IDO1) INCB024360 in patients (pts) with advanced malignancies.
    • (suppl; abstr 3025)
    • Beatty GL DP, Clark J, Shi JG, Newton RC, Schaub R, Maleski J, et al. Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2,3-dioxygenase (IDO1) INCB024360 in patients (pts) with advanced malignancies. J Clin Oncol 31, 2013 (suppl; abstr 3025). http://meetinglibrary.asco.org/content/115661-132. Accessed 21 Nov 2015.
    • (2013) J Clin Oncol , vol.31
    • Beatty G.L, D.P.1    Clark, J.2    Shi, J.G.3    Newton, R.C.4    Schaub, R.5    Maleski, J.6
  • 64
    • 84957077214 scopus 로고    scopus 로고
    • Updated results from a phase 1/2 study of epacadostat (INCB024360) in combination with ipilimumab in patients with metastatic melanoma.
    • ECCO-ESMO 2015: abstract 511. 2015. Accessed 22 Jan 2016.
    • Gibney GT, Hamid O, Lutzky J, Olszanski AJ, Gangadhar TC, Gajewski TF, et al. Updated results from a phase 1/2 study of epacadostat (INCB024360) in combination with ipilimumab in patients with metastatic melanoma. ECCO-ESMO 2015: abstract 511. 2015. http://www.europeancancercongress.org/Scientific-Programme/Abstract-search?abstractid=23278. Accessed 22 Jan 2016.
    • Gibney, G.T.1    Hamid, O.2    Lutzky, J.3    Olszanski, A.J.4    Gangadhar, T.C.5    Gajewski, T.F.6
  • 65
    • 84977161108 scopus 로고    scopus 로고
    • Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment
    • Spranger S, Koblish HK, Horton B, Scherle PA, Newton R, Gajewski TF. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J Immunother Cancer. 2014;2:3.
    • (2014) J Immunother Cancer , vol.2 , pp. 3
    • Spranger, S.1    Koblish, H.K.2    Horton, B.3    Scherle, P.A.4    Newton, R.5    Gajewski, T.F.6
  • 66
    • 84995684655 scopus 로고    scopus 로고
    • Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers
    • Gangadhar TC, Hamid O, Smith DC, Bauer TM, Wasser JS, Luke JJ, et al. Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers. J Immunother Cancer. 2015;3 Suppl 2:O7.
    • (2015) J Immunother Cancer , vol.3 , pp. O7
    • Gangadhar, T.C.1    Hamid, O.2    Smith, D.C.3    Bauer, T.M.4    Wasser, J.S.5    Luke, J.J.6
  • 67
    • 84863115998 scopus 로고    scopus 로고
    • Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape
    • Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 2012;72:917-27.
    • (2012) Cancer Res , vol.72 , pp. 917-927
    • Woo, S.R.1    Turnis, M.E.2    Goldberg, M.V.3    Bankoti, J.4    Selby, M.5    Nirschl, C.J.6
  • 68
    • 79951684125 scopus 로고    scopus 로고
    • PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice
    • Okazaki T, Okazaki IM, Wang J, Sugiura D, Nakaki F, Yoshida T, et al. PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice. J Exp Med. 2011;208:395-407.
    • (2011) J Exp Med , vol.208 , pp. 395-407
    • Okazaki, T.1    Okazaki, I.M.2    Wang, J.3    Sugiura, D.4    Nakaki, F.5    Yoshida, T.6
  • 69
    • 84942887332 scopus 로고    scopus 로고
    • Differential expression of immune-regulatory genes associated with PD-L1 display in melanoma: implications for PD-1 pathway blockade
    • Taube JM, Young GD, McMiller TL, Chen S, Salas JT, Pritchard TS, et al. Differential expression of immune-regulatory genes associated with PD-L1 display in melanoma: implications for PD-1 pathway blockade. Clin Cancer Res. 2015;21:3969-76.
    • (2015) Clin Cancer Res , vol.21 , pp. 3969-3976
    • Taube, J.M.1    Young, G.D.2    McMiller, T.L.3    Chen, S.4    Salas, J.T.5    Pritchard, T.S.6
  • 70
    • 66849095271 scopus 로고    scopus 로고
    • Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy
    • Sabatino M, Kim-Schulze S, Panelli MC, Stroncek D, Wang E, Taback B, et al. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol. 2009;27:2645-52.
    • (2009) J Clin Oncol , vol.27 , pp. 2645-2652
    • Sabatino, M.1    Kim-Schulze, S.2    Panelli, M.C.3    Stroncek, D.4    Wang, E.5    Taback, B.6
  • 71
    • 14644387383 scopus 로고    scopus 로고
    • Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration
    • RESEARCH0035.
    • Panelli MC, Wang E, Phan G, Puhlmann M, Miller L, Ohnmacht GA, et al. Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. Genome Biol. 2002;3(7):RESEARCH0035.
    • (2002) Genome Biol. , vol.3 , Issue.7
    • Panelli, M.C.1    Wang, E.2    Phan, G.3    Puhlmann, M.4    Miller, L.5    Ohnmacht, G.A.6
  • 72
    • 84925373898 scopus 로고    scopus 로고
    • Prognostic and predictive markers for the new immunotherapies
    • Mahoney KM, Atkins MB. Prognostic and predictive markers for the new immunotherapies. Oncology (Williston Park). 2014;28 Suppl 3:39-48.
    • (2014) Oncology (Williston Park) , vol.28 , pp. 39-48
    • Mahoney, K.M.1    Atkins, M.B.2
  • 73
    • 84935474357 scopus 로고    scopus 로고
    • PD-L1 expression as a predictive biomarker in cancer immunotherapy
    • Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14:847-56.
    • (2015) Mol Cancer Ther , vol.14 , pp. 847-856
    • Patel, S.P.1    Kurzrock, R.2
  • 75
    • 84944937210 scopus 로고    scopus 로고
    • Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
    • Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627-39.
    • (2015) N Engl J Med , vol.373 , pp. 1627-1639
    • Borghaei, H.1    Paz-Ares, L.2    Horn, L.3    Spigel, D.R.4    Steins, M.5    Ready, N.E.6
  • 77
    • 84859128199 scopus 로고    scopus 로고
    • Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape.
    • 127ra137.
    • Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4:127ra137.
    • (2012) Sci Transl Med. , vol.4
    • Taube, J.M.1    Anders, R.A.2    Young, G.D.3    Xu, H.4    Sharma, R.5    McMiller, T.L.6
  • 78
    • 84904024273 scopus 로고    scopus 로고
    • Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy
    • Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20:5064-74.
    • (2014) Clin Cancer Res , vol.20 , pp. 5064-5074
    • Taube, J.M.1    Klein, A.2    Brahmer, J.R.3    Xu, H.4    Pan, X.5    Kim, J.H.6
  • 79
    • 84936821508 scopus 로고    scopus 로고
    • Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature.
    • (suppl; abstr 3001).
    • Ribas A, Robert C, Hodi FS, Wolchok JD, Joshua AM, Hwu W-J, et al. Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature. J Clin Oncol. 2015;33:(suppl; abstr 3001).
    • (2015) J Clin Oncol. , pp. 33
    • Ribas, A.1    Robert, C.2    Hodi, F.S.3    Wolchok, J.D.4    Joshua, A.M.5    Hwu, W-J.6
  • 81
    • 84943516465 scopus 로고    scopus 로고
    • Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
    • Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015;350:207-11.
    • (2015) Science , vol.350 , pp. 207-211
    • Allen, E.M.1    Miao, D.2    Schilling, B.3    Shukla, S.A.4    Blank, C.5    Zimmer, L.6
  • 82
    • 84920962202 scopus 로고    scopus 로고
    • Molecular and genetic properties of tumors associated with local immune cytolytic activity
    • Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015;160:48-61.
    • (2015) Cell , vol.160 , pp. 48-61
    • Rooney, M.S.1    Shukla, S.A.2    Wu, C.J.3    Getz, G.4    Hacohen, N.5
  • 83
    • 84928761118 scopus 로고    scopus 로고
    • Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
    • Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348:124-8.
    • (2015) Science , vol.348 , pp. 124-128
    • Rizvi, N.A.1    Hellmann, M.D.2    Snyder, A.3    Kvistborg, P.4    Makarov, V.5    Havel, J.J.6
  • 84
    • 84962161807 scopus 로고    scopus 로고
    • Nivolumab in resected and unresectable melanoma: Immune-related adverse events and association with survival outcomes.
    • (suppl; abstr 9028).
    • F Freeman-Keller ML, Weber JS. Nivolumab in resected and unresectable melanoma: Immune-related adverse events and association with survival outcomes. J Clin Oncol. 2015;33:(suppl; abstr 9028).
    • (2015) J Clin Oncol. , pp. 33
    • Freeman-Keller, F.M.L.1    Weber, J.S.2
  • 85
    • 84944261579 scopus 로고    scopus 로고
    • Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center
    • Horvat TZ, Adel NG, Dang TO, Momtaz P, Postow MA, Callahan MK, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol. 2015;33:3193-8.
    • (2015) J Clin Oncol , vol.33 , pp. 3193-3198
    • Horvat, T.Z.1    Adel, N.G.2    Dang, T.O.3    Momtaz, P.4    Postow, M.A.5    Callahan, M.K.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.